PER 0.00% 10.0¢ percheron therapeutics limited

plenty of news coming soon

  1. 5,063 Posts.
    lightbulb Created with Sketch. 284
    Following the manufacture of sufficient supplies of the drug compound by ANP?s technology partner, Isis Pharmaceuticals Inc., ANP has now commenced formulation of this raw material into injectible product to be used in the clinical trial. This drug product formulation work should be completed in April 2011.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.